Low Use of Medications, Lifestyle Counseling in PAD Patients

Share this content:
Low Use of Medications, Lifestyle Counseling in PAD Patients
Low Use of Medications, Lifestyle Counseling in PAD Patients

WEDNESDAY, May 3, 2017 (HealthDay News) -- Patients with peripheral artery disease (PAD) have low use of medication therapy and lifestyle counseling, according to a study published in the May 9 issue of the Journal of the American College of Cardiology.

Jeffrey S. Berger, M.D., from the New York University School of Medicine in New York City, and Joseph A. Ladapo, M.D., Ph.D., from the David Geffen School of Medicine at the University of California, Los Angeles, examined trends in medication use and lifestyle counseling for 1,982 outpatient visits among patients with PAD from 2005 through 2012.

The researchers found that in 24.3 percent of visits, comorbid coronary artery disease (CAD) was present. There was low medication use for cardiovascular prevention and symptoms of claudication: any antiplatelet therapy in 35.7 percent, statin in 33.1 percent, angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) in 28.4 percent, and cilostazol in 4.7 percent of visits. In 22 percent of visits, exercise or diet counseling was used. Smoking cessation counseling or medication was used during 35.8 percent of visits among current smokers with PAD. Over time there was no significant change in medication use or lifestyle counseling. Compared to patients with PAD alone, those with comorbid CAD and PAD were more likely to be prescribed antiplatelet therapy, statins, ACEI/ARB, and smoking cessation counseling (odds ratios, 2.6, 2.6, 2.6, and 4.4, respectively).

"The use of guideline-recommended therapies in patients with PAD was much lower than expected," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »